Issues, both ethical and practical, in the development and conduct of chemoprevention trials

Current Problems in Cancer

Volumn 28, Issue 4, 2004, Pages 186-200

  Sharp, S Michael ^a   Pentz, Rebecca D ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BETA CAROTENE; SELENIUM; TAMOXIFEN;

CANCER CENTER; CANCER CONTROL; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CORRELATION ANALYSIS; ENDOMETRIUM CANCER; FINANCIAL MANAGEMENT; HEALTH SURVEY; HUMAN; INFORMATION PROCESSING; INFORMED CONSENT; MEDICAL ETHICS; PATIENT MONITORING; PATIENT SELECTION; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; STATISTICAL SIGNIFICANCE;

EID: 4043076933     PISSN: 01470272     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2004.05.006     Document Type: Article

References (41)

1. Sikora K. Developing a global strategy for cancer. Eur J Cancer. 35:1999;24-31
2. Sporn M.B., Dunlop N.M., Newton B.L., Smith J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogues (retinoids). Fed Proc. 35:1976;1332-1338
3. Council for International Organizations of Medical Sciences. International Guidelines for Biomedical Research Involving Human Subjects. Geneva: CIOMS, 1993
4. Mathieu M. New drug development a regulatory overview 5th ed. 2000;Parexel, Waltham, MA
5. Omenn G.S., Goodman G.E., Thornquist M.D., et al. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular mortality. N Engl J Med. 334:1996;1150-1155
6. The effect of vitamin A and beta-carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. N Engl J Med 1994;330:1029-35
7. Hennekens C.H., Buring J.E., Manson J.E., et al. Lack of effect of long-term supplementation with beta-carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 334:1996;1145-1149
8. Seacrist L. Animal tests take a backseat to clinical data. Science. 264:1994;1525
9. Marshall E. Tamoxifen hanging in the balance. Science. 264:1994;1525
10. Meyskens F.L. Jr. Criteria for implementation of large and multi agent clinical chemoprevention trials. J Cell Biochem. 77:(S34):2000;115-120
11. Greenwald P. From carcinogenesis to clinical interventions in cancer prevention. Toxicology. 166:2001;37-45
12. Greenwald P, McDonald SS, Anderson DE. An evidence-based approach to cancer prevention clinical trials. Eur J Cancer Prev 2002;Suppl 2:S43-7
13. Khuri F., Lee J., Lippman E., Kim S., Cooper J.S., et al. Isotretinoin effects on head and neck cancer recurrence and second primary tumors. ASCO Proc. 23:2003;359
14. McLarty J.W., Holiday D.B., Girard W.M., et al. Beta-carotene, vitamin A, and lung cancer chemoprevention results of an intermediate endpoint study. Am J Clin Nutr. 11:1995;1216-1222
15. NIH. An introduction to clinical trials. Available at www.clinicaltrials.gov/ct/gui
16. Lippman S.M., Benner S.E., Hong W.K. Cancer chemoprevention. J Clin Oncol. 12:1994;851-873
17. Viehues HB. Preventive interventionalism and individual liberty. In: Sass, HM, Massye RU, editors. Health care systems: moral conflicts in European and American public policy. Dordrecht: Kluwer Academic, 1988
18. McLeroy K.R., Gottlief N.H., Burdine J.N. The business of health promotion ethical issues and professional responsibilities. Health Educ Q. 14:1987;91-109
19. SELECT data: enrollment statistics (updated 09/04/2003). Available at www.nci.nih.gov/clinicaltrials/developments/SELECT
20. Rufin M.T. IV, Baron J. Recruiting subjects in cancer prevention and control studies. J Cell Biochem. 77(S34):2000
21. Goodman G.E., Valanis B., Meyskens F.L., et al. Strategies for recruitment to a population-based lung cancer prevention trial the CARET experience with heavy smokers. Cancer Epidmiol BioMarkers Prev. 7:1998;405-412
22. Valanis B., Blank J., Glass A. Mailing strategies and costs of recruiting heavy smokers in CARET, a large chemoprevention trial. Control Clin Trials. 19:1998;25-38
23. Lovato L.C., Hill K., Hertert S., Hunningshake D.B., Probsfield J.L. Recruitment for controlled clinical trials literature summary and annotated bibliography. Control Clin Trials. 18:1997;328-352
24. Swanson G.M., Ward A.J. Recruiting minorities into clinical trials toward a participant-friendly system. J Natl Cancer Inst. 87:1995;1747-1759
25. National Commission for the protection of human subjects in biomedical research. The Belmont report: ethical principles and guidelines for the protection of human subjects. April 1978. Available at: www.fda.gov/oc/oha/ toc11.html
26. Duran D.G. "Lack of Hispanics' involvement in research - is it Hispanics or scientists?" Community Genet. 1:1998;183-189
27. Hunningshake D.B., Darby C.A., Probstfield J.L. Recruitment experience in clinical trials literature summary and annotated bibliography. Control Clin Trials. 8:1997;6S-30S
28. Tangrea J.A. Patient participation and compliance in cancer chemoprevention trials issues and concerns. Proc Soc Exp Biol Med. 216:1997;560-565
29. Sharp S.M. Assuring informed consent documents are compliant with regulations. Res Pract. 2:2002;74-81
30. Sharp S.M. Improving the process of obtaining informed consent. Appl Clin Trials. 10:2001;32-38
31. Zvzanski S., Pentz R.D., Kodish E.D. Informed consent for pediatric leukemia research. Cancer. 92:2001;691-700
32. Metcalfe K.A., Narod S.A. Breast Cancer Risk Perception among women who have undergone prophylactic bilateral mastectomy. J Natl Cancer Inst. 94:2002;1564-1568
33. Black W.C., Nease R.F., Tosteson A.N.A. Perceptions of breast cancer risk and screening effectiveness in women younger than 50 years of age. J Natl Cancer Inst. 87:1995;720-731
34. Singletary K. Diet, natural products and cancer chemoprevention. J Nutr. 130:(Suppl):2000;465S-466S
35. Simon C., Zyzanski S.J., Eder M., et al. Groups potentially at risk for making poorly informed decision about entry into clinical trials for childhood cancer. J Clin Oncol. 21:2003;2173-2178
36. Goldstein A.O., Frasier P., Curtis P., et al. Consent form readability in university-sponsored research. J Fam Pract. 42:1996;606-611
37. Grossman S.A., Piantadosi S., Covahey C. Are informed consent forms that describe clinical oncology research protocols readable by most patients and their families? J Clin Oncol. 12:1994;2211-2215
38. Sharp S.M. Readability of informed consent documents for medical device trials. Res Pract. 1:2000;211-214
39. Simplification of informed consent documents: recommendations. National Cancer Institute, updated August 2001. Available at www.nci.nih.gov/ clinicaltrials/understanding/simplification-of-informed-consent-documents
40. Sharp SM. Consent documents for oncology trials: does anybody read these things? Am J Clin Oncol 2004 (in press)
41. Kleihues P. Causes of cancer - a global perspective. Plenary Lecture, 18th UICC International Cancer Congress, Oslo Norway, July 1, 2002